Filters

29 posts found

Resource Type
The state of the art in secondary pharmacology and its impact on the safety of new medicines

Jenkinson, Steve Advanced In Vitro Screening of New Drugs for Proarrhythmic Activity, Genetic Engineering News. 2024 44:5, 48-50

Read More
Supporting an integrated QTc risk assessment using the hERG margin distributions for three positive control agents derived from multiple laboratories and on multiple occasions

Derek J. Leishman, Jessica Brimecombe, William Crumb, Simon Hebeisen, Steve Jenkinson, Peter J. Kilfoil, Hiroshi Matsukawa, Karim Melliti, Yusheng Qu, Journal of Pharmacological and Toxicological Methods, Volume 128, 2024, 107524, ISSN 1056-8719. DOI: 10.1007/978-3-031-52197-3

Copyright prevents linking to the article.

Read More
Advanced in vitro screening of new drugs for proarrhythmic activity

Jenkinson, Steve Advanced In Vitro Screening of New Drugs for Proarrhythmic Activity, Genetic Engineering News. 2024 44:5, 48-50

Read More
Ion channels as targets in drug discovery

Gary Stephens, Edwards Stevens (2024) Springer

DOI: 10.1007/978-3-031-52197-3

Read More
Spontaneous activity in peripheral sensory nerves: a systematic review

Choi, Dongchana; Goodwin, Georgea; Stevens, Edward B.b; Soliman, Nadiac; Namer, Barbarad,e; Denk, Franziskaa,* (2023) PAIN

DOI: 10.1097/j.pain.0000000000003115

Read More
New aryl and acylsulfonamides as state-dependent inhibitors of Nav1.3

Nace Zidar a., Tihomir Tomaˇsiˇc., Danijel Kikelj., Martina Durcik., Jan Tytgat., Steve Peigneur., Marc Rogers., Alexander Haworth., and Robert W. Kirby. (2023) New aryl and acylsulfonamides as state-dependent inhibitors of Nav1.3 voltage-gated sodium channel. European Journal of Medicinal Chemistry, 2023.

Read More
Time is a critical factor when evaluating oligonucleotide therapeutics in human ether-a-go-go-related gene assays

Yusheng Qu., Robert Kirby., Richard Davies., Ayesha Jinat., Stefano Stabilini., Bin Wu., Longchuan Yu., BaoXi Gao., and Hugo M. Vargas. (2023). Time Is a Critical Factor When Evaluating Oligonucleotide Therapeutics in Human Ether-a-Go-Go-Related Gene Assays. Nucleic Acid Therapeutics. Nucleic Acid Therapeutics, 2022.

Read More
Development of ASIC1a ligand-gated ion channel drug screening assays across multiple automated patch clamp platforms

Ridley, J., Manyweathers, S., Tang, R., Goetze, T., Becker, N., Kirby, R., Obergrussberger, A., & Rogers, M. (2022). Development of ASIC1a ligand-gated ion channel drug screening assays across multiple automated patch clamp platforms. Frontiers in Molecular Neuroscience. Frontiers in Molecular Neuroscience, 2022.https://www.frontiersin.org/journals/molecular-neuroscience/articles/10.3389/fnmol.2022.982689/full

Read More
Ion channel discovery – partnering to access specialized expertise

Stevens, E. B and Wright, P. D Future Drug Discovery, 2020.

Read More
Cross-site and cross-platform variability of automated patch clamp assessments of drug effects on human cardiac currents in recombinant cells

Kramer, J.; Himmel, H. M.; Lindqvist, A.; Stoelzle-Feix, S.; Chaudhary, K. W.; Li, D.; Bohme, G. A.; Bridgland-Taylor, M.; Hebeisen, S.; Fan, J.; Renganathan, M.; Imredy, J.; Humphries, E. S. A.; Brinkwirth, N.; Strassmaier, T.; Ohtsuki, A.; Danker, T.; Vanoye, C.; Polonchuk, L.; Fermini, B.; Beck Pierson, J.; Gintant, G. Scientific Reports, 2020, 10; 5627

Read More
1 2 3
Metrion Biosciences

Let’s work together

If you have any questions or would like to discuss your specific assay requirements, we will put you directly in touch with a member of our scientific team. Contact us today to discover more.
Contact us for a quote or discussion
Metrion Biosciences is a contract research organisation (CRO) specialising in high-quality preclinical drug discovery services.
magnifier
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram